Sacituzumab Govitecan Levels and Effects while Breastfeeding
Summary of Use during Lactation
No information is available on the clinical use of sacituzumab govitecan during breastfeeding. Because sacituzumab is a large protein molecule, the amount in milk is likely to be very low. It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal. Govitecan is a small-molecule anticancer drug that might enter milk and be absorbed by the infant. Because of the potential for serious adverse reactions in the breastfed infant, the manufacturer recommends that women not breastfeed during treatment and for at least 1 month after the final dose.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Sacituzumab Govitecan
CAS Registry Number
1491917-83-9
Drug Class
Breast Feeding
Lactation
Milk, Human
Antineoplastic Agents
Antibodies, Monoclonal
Immunoconjugates
Topoisomerase I Inhibitors
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
